Cargando…

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline

Individuals with prodromal Alzheimer’s disease show considerable variability in rates of cognitive decline, which hampers the ability to detect potential treatment effects in clinical trials. Prognostic markers to select those individuals who will decline rapidly within a trial time frame are needed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelkmans, Wiesje, Vromen, Ellen M., Dicks, Ellen, Scheltens, Philip, Teunissen, Charlotte E., Barkhof, Frederik, van der Flier, Wiesje M., Tijms, Betty M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924646/ https://www.ncbi.nlm.nih.gov/pubmed/35310828 http://dx.doi.org/10.1093/braincomms/fcac026

Ejemplares similares

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Single-Subject Grey Matter Graphs in Alzheimer's Disease
por: Tijms, Betty M., et al.
Publicado: (2013)

Correction: Single-Subject Grey Matter Graphs in Alzheimer's Disease
por: Tijms, Betty M., et al.
Publicado: (2013)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
por: Verfaillie, Sander C.J., et al.
Publicado: (2016)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2017)

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
por: ten Kate, Mara, et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship
por: van Loenhoud, Anna Catharina, et al.
Publicado: (2019)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Subjective cognitive decline and self‐reported sleep problems: The SCIENCe project
por: Exalto, Lieza G., et al.
Publicado: (2022)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease
por: Benedictus, Marije R., et al.
Publicado: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study
por: Boomsma, Jooske MF, et al.
Publicado: (2022)

Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
por: Jutten, Roos J., et al.
Publicado: (2021)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Circulating metabolites are associated with brain atrophy and white matter hyperintensities
por: de Leeuw, Francisca A., et al.
Publicado: (2020)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer’s Disease
por: Adriaanse, Sofie M., et al.
Publicado: (2014)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2020)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d5tp0virr9l12qo2ap6277l77g